Merck & Co. Inc. has announced the initiation of the EXPrESSIVE Phase 3 clinical trials to evaluate the safety and efficacy of MK-8527, an investigational once-monthly oral nucleoside reverse transcriptase translocation inhibitor for HIV pre-exposure prophylaxis (PrEP). The trials are being conducted in collaboration with the Gates Foundation. The EXPrESSIVE-10 trial will focus on women and adolescent girls in sub-Saharan Africa, while the EXPrESSIVE-11 trial will target individuals with a greater likelihood of HIV-1 exposure in 16 countries, with enrollment scheduled to begin in August 2025. This decision follows a Phase 2 trial involving 350 participants, which demonstrated favorable safety and pharmacokinetic profiles of MK-8527. Results from this Phase 2 trial were presented during the 13th International AIDS Society Conference on HIV Science in Kigali, Rwanda.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.